You are here

Treating CML

Anything relating to the treatment and therapy available for CML

Post count: 
1 983
Thread count: 
305
Machine name: 
treating_cml

DASISION

A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML

A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for CML in chronic phase

admin's picture
Submitted by admin on Wed, 29/07/2015 - 1:22pm
Leukaemia magazine logo

BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib.

Pages